Terminated PHASE2 INTERVENTIONAL 1-arm NCT06884683

Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma (NivoMet)

A Phase II Study of Nivolumab Combined With Metformin in Pretreated Metastatic Renal Cell Carcinoma (mRCC) Patients. NivoMet TWINS-GU002 Study

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions Metastatic Renal Cell Carcinoma

Interventions Metformin

Updated 1 time since 2025 Last updated: Mar 18, 2025 Started: Sep 17, 2020 Primary completion: Sep 13, 2023 Completion: Sep 13, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow enrollment

Other terminated trials from Fondazione Policlinico Universitario Agostino Gemelli IRCCS

See all terminations from Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other Metastatic Renal Cell Carcinoma trials with similar outcome

Browse all Metastatic Renal Cell Carcinoma trials

A PHASE2 clinical study on Metastatic Renal Cell Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Fondazione Policlinico Universitario Agostino Gemelli IRCCS and has accumulated 1 data snapshot since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

1 version recorded

Terminated — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Data source: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Roma, Italy
• Viterbo, Italy